Reuters logo
BRIEF-Celldex Therapeutics Q3 loss per share $0.20
2017年11月7日 / 下午2点34分 / 13 天前

BRIEF-Celldex Therapeutics Q3 loss per share $0.20

Nov 7 (Reuters) - Celldex Therapeutics Inc

* Q3 revenue $3.9 million versus $2.2 million

* Celldex reports third quarter 2017 results

* Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S

* Q3 loss per share $0.20

* Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S

* Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​

* Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below